Quince Therapeutics, Inc. - Common Stock, par value $0.0001 par value (QNCX)

CUSIP: 22053A107

Q2 2025 13F Holders as of 30 Jun 2025

Type / Class
Equity / Common Stock, par value $0.0001 par value
Shares outstanding
55,541,178
Total 13F shares
7,578,787
Share change
+2,348,519
Total reported value
$12,505,248
Put/Call ratio
0%
Price per share
$1.65
Number of holders
40
Value change
+$3,952,656
Number of buys
16
Number of sells
14

Quarterly Holders Quick Answers

What is CUSIP 22053A107?
CUSIP 22053A107 identifies QNCX - Quince Therapeutics, Inc. - Common Stock, par value $0.0001 par value in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of Quince Therapeutics, Inc. - Common Stock, par value $0.0001 par value (QNCX) as of Q2 2025

As of 30 Jun 2025, Quince Therapeutics, Inc. - Common Stock, par value $0.0001 par value (QNCX) was held by 40 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 7,578,787 shares. The largest 10 holders included Nantahala Capital Management, LLC, VANGUARD GROUP INC, IEQ CAPITAL, LLC, GEODE CAPITAL MANAGEMENT, LLC, RENAISSANCE TECHNOLOGIES LLC, BlackRock, Inc., HighTower Advisors, LLC, Alphabet Inc., Rockefeller Capital Management L.P., and Shay Capital LLC. This page lists 41 institutional shareholders reporting positions in this security for the Q2 2025 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.